Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of “Buy” by Analysts

Climb Bio, Inc. (NASDAQ:CLYM) has been assigned an average rating of “Buy” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $23.0833.

A number of equities research analysts recently commented on the stock. Robert W. Baird set a $21.00 price objective on shares of Climb Bio in a research report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research note on Friday, July 17th. HC Wainwright raised their price target on Climb Bio from $20.00 to $24.00 and gave the company a “buy” rating in a report on Monday. Truist Financial raised their price target on Climb Bio from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Chardan Capital initiated coverage on Climb Bio in a research note on Tuesday, May 5th. They issued a “buy” rating and a $22.00 price target on the stock.

Institutional Investors Weigh In On Climb Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of CLYM. Legal & General Group Plc acquired a new position in shares of Climb Bio during the 2nd quarter worth $45,000. XTX Topco Ltd increased its holdings in shares of Climb Bio by 19.4% in the 4th quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock valued at $139,000 after purchasing an additional 5,668 shares in the last quarter. California State Teachers Retirement System acquired a new stake in shares of Climb Bio in the second quarter valued at about $82,000. Virtu Financial LLC acquired a new stake in shares of Climb Bio in the fourth quarter valued at about $43,000. Finally, Blair William & Co. IL purchased a new stake in Climb Bio during the fourth quarter worth about $44,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Stock Performance

CLYM stock opened at $16.40 on Tuesday. Climb Bio has a one year low of $1.54 and a one year high of $18.14. The stock has a market capitalization of $942.02 million, a PE ratio of -19.76 and a beta of 0.08. The company has a fifty day moving average of $13.45 and a 200-day moving average of $10.20.

Climb Bio (NASDAQ:CLYM) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.03. Equities analysts forecast that Climb Bio will post -0.84 earnings per share for the current fiscal year.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.